// App-Quantinova.ai

BSH2020‐EP‐093 : Combination of Bruton's Tyrosine Kinase (BTK) inhibitor, ibrutinib, with rituximab versus placebo with rituximab in previously untreated patients with follicular lymphoma (FL): a randomized, phase 3 study (Perspective)

Researchers

Presenter

  • S. Rule

Principal Investigators

  • I. Flinn

  • R. Chen

  • L. Kwei

  • A. D. Chu

  • L. I. Gordon

  • N. Fowler

Medical Centers

  • Department of Haematology, Plymouth University Peninsula Schools of Medicine and Dentistry, Plymouth, UK

  • Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN

  • Hematology and Medical Oncology, City of Hope National Medical center, Duarte, CA

  • Biometrics and Clinical Operations

  • Immunology Clinical Development, Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA

  • Department of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Care Center, Chicago, IL

  • Department of Lymphoma and Myeloma, University of Texas M. D. Anderson Cancer Center, Houston, TX

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Oncology (ONC)

Disease

  • Non‐Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Bruton tyrosine kinase

  • Creatinine

Drug/Treatment

  • Ibrutinib

  • Rituximab

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT02947347

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved